2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
HhAntag691
25
Imiquimod
12
Biopsy
12
sonidegib
11
Aminolevulinic Acid
9
cemiplimab
8
Photochemotherapy
8
Nivolumab
8
methyl 5-aminolevulinate
7
Mohs Surgery
7
1-phenyl-3,3-dimethyltriazene
7
Tomography, Optical Coherence
6
Surgical Procedures, Operative
6
Specimen Handling
5
Radiotherapy
5
Itraconazole
5
pembrolizumab
4
daromun
4
Microscopy, Confocal
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Curettage
4
Standard of Care
3
Niacinamide
3
IPI-926
3
CTLA-4 Antigen
3
3-ingenyl angelate
3
tazarotene
2
talimogene laherparepvec
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled